Berardi Rossana, Maccaroni Elena, Onofri Azzurra, Giampieri Riccardo, Bittoni Alessandro, Pistelli Mirco, Scartozzi Mario, Pierantoni Chiara, Bianconi Maristella, Cascinu Stefano
Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy.
Expert Opin Pharmacother. 2009 Oct;10(14):2245-58. doi: 10.1517/14656560903143776.
In Western countries, colorectal cancer is the third most common cancer in terms of incidence and mortality. The management of rectal cancer has undergone and continues to undergo significant evolutions. In the last two decades, new multimodality strategies have been developed. Multimodality treatments have improved the prognosis of locally advanced rectal cancer with local recurrences decreasing from 40% to < 10% and overall survival increasing from 50% to 75% in the last 40 years. This review discusses the role of neoadjuvant chemoradiotherapy regimens used in the standard combined modality treatment programs for rectal cancer and focuses on the ongoing research to improve these regimens.
在西方国家,结直肠癌的发病率和死亡率均位居第三。直肠癌的治疗已经并仍在经历重大变革。在过去二十年中,已开发出新的多模式策略。多模式治疗改善了局部晚期直肠癌的预后,在过去40年中,局部复发率从40%降至<10%,总生存率从50%提高到75%。本文综述了新辅助放化疗方案在直肠癌标准联合治疗方案中的作用,并重点关注了旨在改进这些方案的正在进行的研究。